QuVa Pharma, Inc, a recently formed, national platform for sterile compounding pharmacy services, announces a signed agreement to acquire an FDA-approved biotech pharmaceutical facility in New Jersey. QuVa Pharma currently operates two Texas-based, 503B-registered manufacturing facilities. The 160,000 square foot pharmaceutical facility will extend the production capability and capacity to deliver high-quality, ready-to-use compounded sterile drug preparations to hospitals in the eastern US. The facility will be modified to meet or exceed the FDA’s requirements for sterile manufacturing in the 503B setting, and will include complete in-house product and environmental testing capabilities. Operations are expected to commence in mid-2017.